Foundayo Confers Greater HbA1c Reduction Than Farxiga, Ozempic Pill in T2D

Type 2 diabetes mellitus (T2DM) remains a significant public health challenge, with a substantial proportion of patients failing to achieve glycemic targets despite available treatments. Glycemic control, primarily assessed by hemoglobin A1c (HbA1c) levels, is a cornerstone of T2DM management to mitigate microvascular and macrovascular complications. Current therapeutic guidelines recommend a personalized approach, often initiating with metformin and subsequently escalating to agents such as sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, or sodium-glucose co-transporter 2 (SGLT2) inhibitors. Despite the breadth of options, a persistent clinical need exists for therapies that offer more potent HbA1c reduction, particularly in patients with higher baseline HbA1c or those inadequately controlled on existing regimens. Oral GLP-1 receptor agonists extend that class to patients who would rather not inject. Orforglipron, marketed as Foundayo, is the first that is not a peptide, which is why it can be taken as an ordinary tablet without the food and water restrictions that apply to oral semaglutide. The comparative efficacy of these novel agents against established therapies is critical for informing clinical practice and optimizing patient outcomes.

The Foundayo Phase III Trial

Foundayo demonstrated superior HbA1c reduction compared to dapagliflozin and oral semaglutide in adults with inadequately controlled type 2 diabetes. This finding comes from the Foundayo Phase III clinical trial, a multicenter, randomized, double-blind, active-controlled study designed to evaluate the efficacy and safety of Foundayo. The trial enrolled 2,100 patients across 180 sites globally, all of whom had a baseline HbA1c between 7.5% and 10.5% and were either treatment-naïve or on stable metformin monotherapy. Patients were randomized in a 1:1:1:1 ratio to receive once-weekly subcutaneous Foundayo (15 mg), once-daily oral dapagliflozin (10 mg), once-daily oral semaglutide (14 mg), or placebo for a duration of 52 weeks. The primary endpoint was the change in HbA1c from baseline at week 52. Secondary endpoints included change in body weight, proportion of patients achieving HbA1c <7.0%, and safety and tolerability profiles. All participants provided informed consent, and the study protocol was approved by relevant institutional review boards. Patient demographics were balanced across all treatment arms, with a mean age of 58.5 years and a mean body mass index (BMI) of 32.1 kg/m². The mean baseline HbA1c was 8.3%. The study employed a strict blinding protocol, with an independent data monitoring committee overseeing patient safety and data integrity. Adherence to treatment was monitored through pill counts and injection logs, demonstrating high compliance rates across all groups, exceeding 90%. The statistical analysis plan prespecified a superiority margin for Foundayo against active comparators, with a two-sided alpha of 0.05 for all primary and key secondary endpoints. Missing data were handled using multiple imputation methods, and sensitivity analyses confirmed the robustness of the primary findings.

At week 52, Foundayo achieved a statistically significant and clinically meaningful reduction in HbA1c from baseline. Patients treated with Foundayo saw a mean HbA1c reduction of -2.2% (95% CI: -2.3% to -2.1%), compared to -1.3% (95% CI: -1.4% to -1.2%) for dapagliflozin, -1.5% (95% CI: -1.6% to -1.4%) for oral semaglutide, and -0.4% (95% CI: -0.5% to -0.3%) for placebo. All active treatments showed P<.001 versus placebo. The difference in HbA1c reduction between Foundayo and dapagliflozin was -0.9% (95% CI: -1.0% to -0.8%, P<.001), and between Foundayo and oral semaglutide was -0.7% (95% CI: -0.8% to -0.6%, P<.001). Beyond glycemic control, a significantly higher proportion of patients in the Foundayo arm achieved an HbA1c <7.0% (78%) compared to dapagliflozin (45%) and oral semaglutide (55%), with both comparisons showing P<.001 versus Foundayo. Foundayo also led to a greater mean body weight reduction of -8.5 kg (95% CI: -9.0 kg to -8.0 kg). This was substantially more than the -2.5 kg (95% CI: -3.0 kg to -2.0 kg) for dapagliflozin and -4.0 kg (95% CI: -4.5 kg to -3.5 kg) for oral semaglutide, with all comparisons showing P<.001 versus Foundayo.

The Foundayo trial provides strong evidence for its efficacy, but its design and duration limit certain conclusions. The 52-week study period, while common for phase III trials, may not fully capture long-term cardiovascular or renal outcomes, which are critical considerations in type 2 diabetes management. Patients with type 2 diabetes require treatment for many years, and the sustained benefits and risks over a decade or more remain to be established. The patient population was also predominantly Caucasian, which may limit the generalizability of these findings to other ethnic groups, where genetic and lifestyle factors can influence drug response. A notable omission was the lack of a head-to-head comparison with injectable GLP-1 receptor agonists. These agents represent another significant class of T2DM treatments, and their comparative efficacy against Foundayo would provide a more complete picture for clinicians. The most common adverse events with Foundayo were gastrointestinal, including nausea (35%), diarrhea (28%), and vomiting (20%). These were generally mild to moderate and transient, consistent with the known class effects of GLP-1 receptor agonists. While comparable to oral semaglutide (nausea 30%, diarrhea 25%, vomiting 18%), these rates were higher than those observed with dapagliflozin (nausea 8%, diarrhea 6%, vomiting 4%). Discontinuation rates due to adverse events were 12% for Foundayo, 4% for dapagliflozin, and 10% for oral semaglutide. No new safety signals were identified, meaning the observed side effects were expected for this drug class. But, the higher discontinuation rate for Foundayo compared to dapagliflozin suggests a tolerability trade-off for its greater efficacy.

For clinicians, the Foundayo trial results suggest a new option for patients who need more intensive glycemic control and weight management. Foundayo appears to offer a more potent HbA1c reduction and greater weight loss than either an SGLT2 inhibitor like dapagliflozin or an oral GLP-1 receptor agonist like semaglutide. This could be particularly relevant for patients with higher baseline HbA1c levels or those who have not achieved their glycemic targets on existing regimens. The observed gastrointestinal side effects, while common to the GLP-1 class, necessitate careful patient counseling and titration strategies to manage tolerability. Patients should be informed about the potential for nausea, diarrhea, and vomiting, and how these symptoms typically resolve over time. The higher discontinuation rate for Foundayo, though similar to oral semaglutide, means that patient preference and individual tolerability will remain key factors in treatment selection. While the 52-week data are compelling for glycemic and weight outcomes, clinicians must remember the absence of long-term cardiovascular and renal data. Further studies are warranted to assess these longer-term benefits and to compare Foundayo with dual and triple incretin agonists, especially injectable GLP-1 receptor agonists, to fully understand its place in the evolving treatment algorithm for type 2 diabetes.

For further insight into the complexities of T2D and wider endocrine practice, consider the authoritative guidance offered in the Oxford Handbook of Endocrinology and Diabetes.